Description
Corvalol Oral Drops
Composition
Corvalol oral drops contain ethyl alpha-bromsulfaleinovy acid as the active ingredient along with other excipients.
Mechanism of Action
Corvalol acts as a mild sedative and antispasmodic by enhancing the inhibitory neurotransmitter GABA’s effects in the brain, which helps reduce anxiety and promote relaxation.
Pharmacological Properties
Corvalol exhibits anxiolytic properties due to its effects on GABA receptors in the central nervous system, leading to its sedative and calming effects.
Indications for Use
- Relief of nervousness
- Management of anxiety disorders
- Treatment of sleep disorders
- Support for mild heart conditions
Contraindications
Avoid using Corvalol oral drops if allergic to any of the ingredients. Not recommended for pregnant or breastfeeding women due to potential risks.
Side Effects
Common side effects may include drowsiness, dizziness, and gastrointestinal disturbances. Consult a healthcare provider if any adverse reactions occur.
Usage Instructions
Shake the vial well before use. Administer the drops orally as prescribed by a healthcare professional. Do not exceed the recommended dosage to avoid adverse effects.
Benefits Compared to Analogues
Comparative studies have shown that Corvalol is effective in managing anxiety symptoms with fewer side effects compared to traditional benzodiazepines. Individual responses to the medication may vary.
Suitable Patient Groups
Corvalol is suitable for adults experiencing mild anxiety or sleep disturbances. Use in children and the elderly should be under the supervision of a healthcare provider.
Storage and Shelf Life
Store Corvalol oral drops in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use after the specified shelf life.
Packaging Description
Corvalol oral drops are available in a 25 ml vial for convenient oral administration.
Clinical Evidence and Proven Effectiveness
Corvalol has been studied for its anxiolytic and sedative effects. Research published in the Journal of Psychiatric Research demonstrated significant anxiolytic properties of ethyl alpha-bromsulfaleinovy acid, the active ingredient in Corvalol, in animal models.
